The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss

Journal of Nutritional Biochemistry

Volumn 22, Issue 1, 2011, Pages 8-15

  Kim, Tae Ho ^a,b   Jung, Ji Won ^a   Ha, Byung Geun ^a   Hong, Jung Min ^a   Park, Eui Kyun ^a,c   Kim, Hyun Ju ^a   Kim, Shin Yoon ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Bone loss; Bone resorption; Flavonoid; Luteolin; Osteoclast; Ovariectomy

Indexed keywords

BIOCHEMICAL MARKER; LUTEOLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE ATROPHY; BONE DENSITY; BONE MARROW CELL; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CORTICAL BONE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FEMUR; LOW DRUG DOSE; MICRO-COMPUTED TOMOGRAPHY; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; TRABECULAR BONE;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUTEOLIN; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RANDOM ALLOCATION;

ANIMALIA; MUS;

EID: 78649931136     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.11.002     Document Type: Article

References (40)

1. Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 2002, 1:784-796.
2. Kelly P.J. Is osteoporosis a genetically determined disease?. Br J Obstet Gynaecol 1996, 103(Suppl 13):20-26. [discussion 26-7].
3. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
4. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis-the second decade. Endocrinology 1998, 139:2659-2661.
5. Weitzmann M.N., Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006, 116:1186-1194.
6. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
7. Reid I.R. Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opin Drug Saf 2002, 1:93-107.
8. Yeh I.T. Postmenopausal hormone replacement therapy: endometrial and breast effects. Adv Anat Pathol 2007, 14:17-24.
9. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52:673-751.
10. Dang Z.C., Lowik C. Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol Metab 2005, 16:207-213.
11. Picherit C., Coxam V., Bennetau-Pelissero C., Kati-Coulibaly S., Davicco M.J., Lebecque P., et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000, 130:1675-1681.
12. Ishimi Y., Arai N., Wang X., Wu J., Umegaki K., Miyaura C., et al. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000, 274:697-701.
13. Park J.A., Ha S.K., Kang T.H., Oh M.S., Cho M.H., Lee S.Y., et al. Protective effect of apigenin on ovariectomy-induced bone loss in rats. Life Sci 2008, 82:1217-1223.
14. Wattel A., Kamel S., Mentaverri R., Lorget F., Prouillet C., Petit J.P., et al. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 2003, 65:35-42.
15. Horcajada-Molteni M.N., Crespy V., Coxam V., Davicco M.J., Remesy C., Barlet J.P. Rutin inhibits ovariectomy-induced osteopenia in rats. J Bone Miner Res 2000, 15:2251-2258.
16. Xagorari A., Papapetropoulos A., Mauromatis A., Economou M., Fotsis T., Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 2001, 296:181-187.
17. Kotanidou A., Xagorari A., Bagli E., Kitsanta P., Fotsis T., Papapetropoulos A., et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Respir Crit Care Med 2002, 165:818-823.
18. Park E., Kum S., Wang C., Park S.Y., Kim B.S., Schuller-Levis G. Anti-inflammatory activity of herbal medicines: inhibition of nitric oxide production and tumor necrosis factor-alpha secretion in an activated macrophage-like cell line. Am J Chin Med 2005, 33:415-424.
19. Choi E.M. Modulatory effects of luteolin on osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. Cell Biol Int 2007, 31:870-877.
20. Zhang J., Ahn M.J., Sun Q.S., Kim K.Y., Hwang Y.H., Ryu J.M., et al. Inhibitors of bone resorption from Halenia corniculata. Arch Pharm Res 2008, 31:850-855.
21. Ha B.G., Hong J.M., Park J.Y., Ha M.H., Kim T.H., Cho J.Y., et al. Proteomic profile of osteoclast membrane proteins: identification of Na+/H+ exchanger domain containing 2 and its role in osteoclast fusion. Proteomics 2008, 8:2625-2639.
22. Faccio R., Takeshita S., Zallone A., Ross F.P., Teitelbaum S.L. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 2003, 111:749-758.
23. Battaglino R., Kim D., Fu J., Vaage B., Fu X.Y., Stashenko P. c-myc is required for osteoclast differentiation. J Bone Miner Res 2002, 17:763-773.
24. Yagi M., Ninomiya K., Fujita N., Suzuki T., Iwasaki R., Morita K., et al. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 2007, 22:992-1001.
25. Meli R., Pacilio M., Raso G.M., Esposito E., Coppola A., Nasti A., et al. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology 2004, 145:3115-3121.
26. Tommasini S.M., Morgan T.G., van der Meulen M., Jepsen K.J. Genetic variation in structure-function relationships for the inbred mouse lumbar vertebral body. J Bone Miner Res 2005, 20:817-827.
27. Sheng Z.F., Dai R.C., Wu X.P., Fang L.N., Fan H.J., Liao E.Y. Regionally specific compensation for bone loss in the tibial trabeculae of estrogen-deficient rats. Acta Radiol 2007, 48:531-539.
28. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991, 15:175-191.
29. Kleerekoper M., Villanueva A.R., Stanciu J., Rao D.S., Parfitt A.M. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 1985, 37:594-597.
30. Wronski T.J., Lowry P.L., Walsh C.C., Ignaszewski L.A. Skeletal alterations in ovariectomized rats. Calcif Tissue Int 1985, 37:324-328.
31. Szulc P., Delmas P.D. Biochemical markers of bone turnover in men. Calcif Tissue Int 2001, 69:229-234.
32. Bahlous A., Kalai E., Hadj Salah M., Bouzid K., Zerelli L. Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis. Tunis Med 2006, 84:751-757.
33. Notoya M., Arai R., Katafuchi T., Minamino N., Hagiwara H. A novel member of the calcitonin gene-related peptide family, calcitonin receptor-stimulating peptide, inhibits the formation and activity of osteoclasts. Eur J Pharmacol 2007, 560:234-239.
34. Hotokezaka H., Sakai E., Ohara N., Hotokezaka Y., Gonzales C., Matsuo K., et al. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem 2007, 101:122-134.
35. Ingham E., Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005, 26:1271-1286.
36. Bai X.C., Lu D., Bai J., Zheng H., Ke Z.Y., Li X.M., et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 2004, 314:197-207.
37. Suda N., Morita I., Kuroda T., Murota S. Participation of oxidative stress in the process of osteoclast differentiation. Biochim Biophys Acta 1993, 1157:318-323.
38. Seelinger G., Merfort I., Schempp C.M. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 2008, 74:1667-1677.
39. Ueda H., Yamazaki C., Yamazaki M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull 2002, 25:1197-1202.
40. Harris G.K., Qian Y., Leonard S.S., Sbarra D.C., Shi X. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells. J Nutr 2006, 136:1517-1521.